DRUG NAME: Abiraterone - BC Cancer Agency
DRUG NAME: Abiraterone - BC Cancer Agency
DRUG NAME: Abiraterone - BC Cancer Agency
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Abiraterone</strong>ORGAN SITESIDE EFFECTClinically important side effects are in bold, italicsmetabolism and nutritionmusculoskeletal andconnective tissuerenal and urinaryrespiratory, thoracic andmediastinalvascularbilirubin, increased (6%, severe
<strong>Abiraterone</strong>SUPPLY AND STORAGE:Oral: Janssen Inc. supplies abiraterone as a 250 mg tablet. Selected non-medicinal ingredient: lactose. Store atroom temperature. 1DOSAGE GUIDELINES:Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease,response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count(ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due tocytotoxic/radiation therapy or with other toxicities.Adults:<strong>BC</strong>CA usual dose noted in bold, italicsOral: 1 g once daily 8Administer on an empty stomach (one hour before or two hours after food). 1Dosage in renal failure: no adjustment required 1Dosage in hepatic failure: may reduce dose to 250 mg once daily in moderate hepatic impairment 4,5Dosage in dialysis: no adjustment required 1Children:no information foundREFERENCES:1. Janssen Inc. ZYTIGA® product monograph. Toronto, Ontario; 26 July 2011.2. Salem M, Garcia JA. <strong>Abiraterone</strong> acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr OncolRep 2011(13):92-96.3. Drug Facts and Comparisons® (database on the Internet). <strong>Abiraterone</strong>. Wolters Kluwer Health Inc. Facts and Comparisons®eAnswers, June 2011. Available at: http://online.factsandcomparisons.com. Accessed 20 September 2011.4. Centocor Ortho Biotech Inc. ZYTIGA® product monograph. Horsham, Pennsylvania; April 2011.5. Kim Chi MD. Personal communication. <strong>BC</strong> <strong>Cancer</strong> <strong>Agency</strong> Genitourinary Tumour Group; 01 October 2011.6. <strong>BC</strong> <strong>Cancer</strong> <strong>Agency</strong>. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting inAdults. Vancouver, British Columbia: <strong>BC</strong> <strong>Cancer</strong> <strong>Agency</strong>; 1 Mar 2011.7. de Bono JS, Logothetis CJ, Arturo M, et al. <strong>Abiraterone</strong> and increased survival in metastatic prostate cancer. NEJM2011;364(21):1995-2005.8. <strong>BC</strong> <strong>Cancer</strong> <strong>Agency</strong> Genitourinary Tumour Group. (UGUPABI) <strong>BC</strong>CA Protocol Summary for Palliative Therapy for MetastaticCastration Resistant Prostate <strong>Cancer</strong> Using <strong>Abiraterone</strong> and Prednisone after Failure of Docetaxel Therapy. Vancouver, BritishColumbia: <strong>BC</strong> <strong>Cancer</strong> <strong>Agency</strong>; 1 September 2011.<strong>BC</strong> <strong>Cancer</strong> <strong>Agency</strong> <strong>Cancer</strong> Drug Manual © Page 4 of 4 <strong>Abiraterone</strong>Developed: 1 November 2011Revised:
Change language